NaPro receives paclitaxel administration patent
NaPro receives paclitaxel administration patent
NaPro BioTherapeutics in Boulder, CO, has been granted a U.S. patent relating to a novel method of administering paclitaxel. This patented method involves administrating smaller, more frequent doses of the drug over a shorter infusion time compared with the administration schedule currently approved by the FDA for Bristol-Meyers Squibb's paclitaxel product.
However, the patent application was based on data derived from in vitro and animal stud-ies and treatment of cancer patients using the patented method, and no controlled clinical trials have been performed.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.